All In Biotech

Investigational drug · Phase 2

VVD-133214

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Adenocarcinoma.

Phase 2

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "VVD-133214"

First trial start

2026

Sep 11, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VVD-133214", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Colorectal Adenocarcinoma

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "VVD-133214" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Colorectal Adenocarcinoma

  • Tmod CAR T-cell TherapyA2B530, A2B694Phase 23 trials

    A2 Biotherapeutics Inc. · Solid Tumor, Adult, Colorectal Cancer, Colorectal Adenocarcinoma

  • AK129Phase 22 trials

    Akeso · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma

  • DKN-01LY2812176Phase 21 trial

    Leap Therapeutics, Inc. · Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer

  • TST003Phase 21 trial

    Transcenta Therapeutics (Hangzhou) Co., Ltd. · Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.